Research
Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) and cardiovascular death in people with type 2 diabetes and established CVD.
GLP-1 receptor agonists are effective medications that reduce heart attack and stroke risk in people with diabetes or existing heart disease. Access is improving but remains a barrier due to cost.
GoodSupportsHIGH confidence
Among people with type 2 diabetes who took GLP-1RAs a 14% reduction in major adverse cardiovascular events (MACE) and cardiovascular death, and a 13% reduction in hospitalisation for heart failure were found. In people with CVD and no type 2 diabetes, GLP-1RAs reduced major adverse cardiovascular events (MACE) and non-fatal myocardial infarction by 20% and 28%, respectively
Why this rating
Based on a meta-analysis of 10 trials involving over 85,000 participants.
Source
The Weight of Cardiovascular Diseases: Addressing the Global Cardiovascular Crisis Associated with Obesity
Francisco López-Jiménez et al. · Global Heart · 2025
DOI 10.5334/gh.1451
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity acts as an independent risk factor and driver for cardiovascular diseases through mechanisms including insulin resistance, endothelial dysfunction, systemic inflammation, and neurohormonal activation, leading to hypertension, heart failure, coronary artery disease, and stroke.Strong
- Reducing global obesity prevalence to 2019 levels could save an estimated US$2.2 trillion annually by 2060 through healthcare and productivity-related cost savings.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →